Last reviewed · How we verify
Azithromycin 1 gram IV
Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and stopping bacterial growth.
Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and stopping bacterial growth. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Acute otitis media.
At a glance
| Generic name | Azithromycin 1 gram IV |
|---|---|
| Sponsor | Thomas Jefferson University |
| Drug class | Macrolide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Azithromycin is a macrolide antibiotic that binds irreversibly to the bacterial 50S ribosomal subunit, blocking the translocation of peptides and inhibiting protein synthesis. This bacteriostatic action prevents bacterial replication and allows the immune system to clear the infection. It has broad-spectrum activity against many gram-positive and gram-negative bacteria, as well as atypical organisms.
Approved indications
- Community-acquired pneumonia
- Acute bacterial sinusitis
- Acute otitis media
- Pharyngitis/tonsillitis
- Uncomplicated skin and soft tissue infections
- Sexually transmitted infections (chlamydia, gonorrhea)
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
- Vomiting
- QT prolongation
- Hepatotoxicity
- Clostridium difficile infection
Key clinical trials
- Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial (PHASE4)
- International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 (PHASE2)
- Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia (PHASE4)
- Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azithromycin 1 gram IV CI brief — competitive landscape report
- Azithromycin 1 gram IV updates RSS · CI watch RSS
- Thomas Jefferson University portfolio CI